Solvonis Therapeutics PLC
SVNS · Main Market · Health Care · mcap £8.3m · 0.1p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 06 Oct 26 | Investor Webinar – 15 October 2026
Building a leader in addiction and mental health therapeutics |
+3.0% | |
| 30 Sep 26 | Notification of Admission of Shares and TVR
LONDON - 30 September 2026 - Solvonis Therapeutics plc (LSE: SVNS), a late clinical-stage biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders, a |
+0.0% | |
| 30 Sep 26 | Results | Unaudited interim results
H1 2026 loss £1.4m, cash £659k; £1.3m placing completed post-period; clinical programmes advanced. |
+0.0% |
| 29 Sep 26 | New Analysis Identifies Major AUD Breakthrough
SVN-001 showed 67% reduction in heavy drinking days versus placebo, ahead of naltrexone and GLP-1 therapies in cross-trial analysis. |
+0.0% | |
| 03 Sep 26 | Vital Patent milestone achieved– SVN 114
European Patent Office issues composition-of-matter allowance for SVN-114 PTSD candidate patent. |
+1.7% | |
| 25 Aug 26 | Solvonis Raises £1.3 Million
Solvonis raises £1.3 million through placing to fund SVN-001, SVN-002 and SVN-015 clinical programmes. |
−12.9% | |
| 11 Aug 26 | Solvonis to Present at WTR Conference
CEO to present at WTR Virtual Insights Conference on 22-23 September 2026 and hold investor meetings. |
+0.0% | |
| 06 Aug 26 | SVN-015 Advances into Further NIDA-Funded Studies
SVN-015 advances into further NIDA-funded preclinical studies after encouraging cardiac ion-channel screening results. |
+3.6% | |
| 13 Jul 26 | Research Coverage Initiation
Water Tower Research initiates coverage of Solvonis, highlighting valuation opportunity relative to CNS and addiction medicine peers. |
+7.4% | |
| 22 Jun 26 | Announces Positive Bridging Data Supporting
Positive preclinical pharmacokinetic data supports planned FDA 505(b)(2) pathway for SVN-002 esketamine in alcohol use disorder. |
+11.1% | |
| 19 Jun 26 | Result of AGM
LONDON - June 19, 2026 - Solvonis Therapeutics plc (LSE: SVNS) ("Solvonis" or the "Company"), a late clinical stage biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous s |
−0.5% | |
| 05 May 26 | CSO Speaks at National Research Meeting
Chief Scientific Officer to speak on psychedelic therapy for addictions at U.S. National Institutes of Health meeting. |
−6.0% | |
| 29 Apr 26 | Results | Final Results
FY2025 results: £1.72m cash at year-end; Board prioritises advancing SVN-001 Phase 3 over earlier partnering to maximise shareholder value. |
−10.8% |
| 22 Apr 26 | Appointment of Water Tower Research
Solvonis appoints Water Tower Research to provide U.S. market research and investor engagement services. |
−1.6% | |
| 20 Apr 26 | US CNS Executive Order
Trump Executive Order on CNS therapies welcomed as positive signal for company's addiction and psychiatry pipeline. |
+9.3% | |
| 08 Apr 26 | Granted U.S. Patent from PTSD Discovery Programme
Solvonis granted second U.S. patent for monoamine modulator compound series from PTSD programme. |
+0.0% | |
| 31 Mar 26 | Granted U.S. Patent from PTSD Discovery Programme
U.S. patent granted for monoamine modulator compound series from PTSD discovery programme. |
−2.0% | |
| 10 Mar 26 | SVN-114 selected for PTSD discovery programme
SVN-114 selected as lead candidate for PTSD discovery programme following preclinical pharmacology results. |
+0.4% | |
| 28 Jan 26 | Expansion of SVN-015 into depression
SVN-015 expanded into depression treatment following positive preclinical data showing activity comparable to fluoxetine. |
−5.6% | |
| 07 Jan 26 | US Patent allowance for PTSD discovery programme
US patent allowance received for PTSD discovery programme compounds ahead of lead candidate selection. |
+3.2% | |
| 22 Dec 25 | Research and Development Update – Q4 2025
SVN-001 Phase 3 trial for severe alcohol use disorder progressing with top-line results expected late 2027/early 2028; multiple 2026 catalysts across pipeline. |
−10.7% | |
| 03 Dec 25 | SVN-015 accepted into US NIDA funded programme
SVN-015 accepted into US NIDA-funded addiction treatment programme for methamphetamine and cocaine addiction. |
+2.5% | |
| 31 Oct 25 | Corporate Structure Update and Issue of Options
Corporate restructuring to consolidate R&D operations and simplification of group structure completed; options and equity issued. |
−3.1% | |
| 27 Oct 25 | Appoints global biopharma leader Paul Carter
Paul Carter appointed Non-Executive Director, granted 21 million share options at £0.0034 per share. |
+0.0% | |
| 16 Oct 25 | Raises £1.25 Million to Accelerate Programmes
Solvonis raises £1.25m through share subscription at £0.0033 per share to accelerate CNS programmes. |
−2.6% |
Company filings. Not investment advice.